Our Work

What is Idiopathic Pulmonary Fibrosis?

Idiopathic Pulmonary Fibrosis affects 200,000 US patients a year and 5 million world-wide.*

So what is Vasoactive Intestinal Peptide?

Our development is using a novel Vasoactive Intestinal Peptide (VIP) drug to treat Pulmonary Fibrosis and lung injury. VIP is a naturally occurring molecular peptide in the body that helps with decreasing inflammation and upregulates healing properties. VIP has proven clinical efficacy in patients with coronary artery disease, asthma, pulmonary hypertension, COPD, sarcoidosis, and an FDA safety trial (Phase I) in sepsis. Animal studies improve models of Crohn’s Disease, rheumatoid arthritis, cystic fibrosis, and Iraq Afghanistan War Lung Injury, with potential for treating World Trade Center Lung Injury.